About lab
Wilson2012 - tumor vaccine efficacy Lab
Curated immunology lab using the bundled source model as the scientific source of truth.
What You'll See
This captured run documents the default Wilson2012 - tumor vaccine efficacy configuration for 10.0 time units with a 1.0 communication step. Default inputs include Initial Unresolved Tumor Observable 1, Initial Unresolved Tumor Observable 2, Initial Unresolved Tumor Observable 3, and Initial Unresolved Tumor Observable 4. Reported outputs include unresolved_tumor_observable_1, unresolved_tumor_observable_2, unresolved_tumor_observable_3, and unresolved_tumor_observable_4. The screenshots below pair the run-interpretation table with Tumor-immune burden and Largest state excursions so the README shows both trajectories and the strongest state changes from the same dark-mode run.
Output Visualizations
The run-interpretation table summarizes the configured Wilson2012 - tumor vaccine efficacy simulation and its final-state diagnostics.
The Tumor-immune burden time series follows the selected immune, pathogen, tumor, or signaling quantities across the simulated horizon.
The largest state excursions chart ranks the state variables that moved furthest during the run.
The paper describes a model of antitumor vaccine therapy.Created by COPASI 4.25 (Build 207) This model is described in the article: A Mathematical Model of the Enhancement of Tumor Vaccine Efficacy by. It can be used to explore immune response dynamics and compare pathway-level behavior across conditions.
Runtime
Runs
Metadata
Manifest
{
"io": {
"inputs": [
{
"name": "initial_unresolved_tumor_observable_1",
"label": "Initial Unresolved Tumor Observable 1",
"units": "substance",
"default": 3,
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.initial_unresolved_tumor_observable_1",
"description": "Initial Unresolved Tumor Observable 1. Sets the initial value of bundled SBML species `T`."
},
{
"name": "initial_unresolved_tumor_observable_2",
"label": "Initial Unresolved Tumor Observable 2",
"units": "substance",
"default": 0,
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.initial_unresolved_tumor_observable_2",
"description": "Initial Unresolved Tumor Observable 2. Sets the initial value of bundled SBML species `B`."
},
{
"name": "initial_unresolved_tumor_observable_3",
"label": "Initial Unresolved Tumor Observable 3",
"units": "substance",
"default": 100,
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.initial_unresolved_tumor_observable_3",
"description": "Initial Unresolved Tumor Observable 3. Sets the initial value of bundled SBML species `E`."
},
{
"name": "initial_unresolved_tumor_observable_4",
"label": "Initial Unresolved Tumor Observable 4",
"units": "substance",
"default": 1,
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.initial_unresolved_tumor_observable_4",
"description": "Initial Unresolved Tumor Observable 4. Sets the initial value of bundled SBML species `R`."
},
{
"name": "initial_unresolved_tumor_observable_5",
"label": "Initial Unresolved Tumor Observable 5",
"units": "substance",
"default": 0,
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.initial_unresolved_tumor_observable_5",
"description": "Initial Unresolved Tumor Observable 5. Sets the initial value of bundled SBML species `V`."
},
{
"name": "tgfb_decay_rate",
"label": "Tgfb Decay Rate",
"units": "unit_1",
"default": 0.0007,
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.tgfb_decay_rate",
"description": "Tgfb Decay Rate. Sets bundled SBML parameter `d`."
}
],
"outputs": [
{
"name": "unresolved_tumor_observable_1",
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.unresolved_tumor_observable_1"
},
{
"name": "unresolved_tumor_observable_2",
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.unresolved_tumor_observable_2"
},
{
"name": "unresolved_tumor_observable_3",
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.unresolved_tumor_observable_3"
},
{
"name": "unresolved_tumor_observable_4",
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.unresolved_tumor_observable_4"
},
{
"name": "unresolved_tumor_observable_5",
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.unresolved_tumor_observable_5"
},
{
"name": "state",
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.state"
},
{
"name": "summary",
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.summary"
},
{
"name": "species_labels",
"maps_to": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.species_labels"
}
]
},
"title": "Wilson2012 - tumor vaccine efficacy Lab",
"models": [
{
"path": "owned/models/immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model",
"alias": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model",
"provenance": {
"owned_path": "owned/models/immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model"
}
},
{
"path": "owned/models/visualisation",
"alias": "visualisation",
"provenance": {
"owned_path": "owned/models/visualisation"
}
}
],
"wiring": [
{
"to": [
"visualisation.immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model_state"
],
"from": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.state"
},
{
"to": [
"visualisation.immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model_summary"
],
"from": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.summary"
},
{
"to": [
"visualisation.immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model_species_labels"
],
"from": "immunology_sbml_wilson2012_tumor_vaccine_efficacy_biomd0000000791_model.species_labels"
}
],
"runtime": {
"duration": 10,
"initial_inputs": {},
"communication_step": 1
},
"description": "The paper describes a model of antitumor vaccine therapy.Created by COPASI 4.25 (Build 207) This model is described in the article: A Mathematical Model of the Enhancement of Tumor Vaccine Efficacy by. It can be used to explore immune response dynamics and compare pathway-level behavior across conditions.",
"schema_version": "2.0"
}Sign in to start your own run. Public-lab history stays visible here.
Select a run from History to view its results.